文献速递血管炎

抗中性粒细胞胞质抗体相关性血管炎中严重感染的危险因素

Risk factors for serious infections in ANCA-associated vasculitis.
PubMed 文献 · Ann Rheum Dis · 2023-01-26

基于RAVE试验197例患者数据,分析抗中性粒细胞胞质抗体相关性血管炎(AAV)严重感染的危险因素。22例严重感染中18例(82%)发生于入组后6个月内,呼吸道感染最常见(15/22,68%)。Cox回归显示基线血清IgM水平较高与严重感染风险相关,基线总CD19+B细胞数较高及使用甲氧苄啶-磺胺甲噁唑(TMP/SMX)预防耶氏肺孢子菌与严重感染风险降低相关;TMP/SMX在RTX组和CYC/AZA组均与较低严重感染风险相关。

要点

  • 22例严重感染中18例(82%)发生于入组后6个月内,呼吸道感染占68%(15/22)。
  • 基线血清IgM水平较高与严重感染风险相关,基线总CD19+B细胞数较高与风险降低相关。
  • 低剂量TMP/SMX预防在RTX组和CYC/AZA组均与严重感染风险降低相关。

核心结论

  • 使用低剂量TMP/SMX与接受RTX或CYC/AZA治疗的AAV患者严重感染风险降低相关。
  • 治疗开始时B细胞亚群减少可能是免疫能力降低的有用相关指标。

研究设计与样本

  • 分析RAVE试验中招募的197例患者数据,患者接受利妥昔单抗(RTX)或环磷酰胺(CYC)后接阿扎胞苷(AZA)治疗。

主要发现

  • 22例严重感染中18例(82%)发生于入组后6个月内,呼吸道感染最常见(15/22,68%)。
  • 基线时,接受RTX或CYC/AZA治疗的严重感染患者CD19+细胞绝对数较低,而CD5+B和CD3+T细胞在组间无差异。
  • Cox回归分析中,基线血清IgM水平较高与严重感染风险相关,基线总CD19+B细胞数较高及使用TMP/SMX预防耶氏肺孢子菌与严重感染风险降低相关。
  • 使用TMP/SMX与接受RTX或CYC/AZA两组患者严重感染风险降低均相关。

关键数值与推荐

  • 严重感染定义为≥3级(根据不良事件通用术语标准第3.0版)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Severe infections contribute to morbidity and mortality in antineutrophil cytoplasm antibody-associated vasculitis (AAV). This study aimed to identify risk factors associated with severe infections in participants of the Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (RAVE) trial. METHODS: Data on 197 patients recruited into the RAVE trial were analysed. Participants received either rituximab (RTX) or cyclophosphamide (CYC), followed by azathioprine (AZA). Clinical and laboratory data of patients with and without severe infections (≥grade 3, according to the Common Terminology Criteria for Adverse Events version 3.0) were compared. Risk factors for severe infections were investigated using Cox-regression models. RESULTS: Eighteen of 22 (82%) severe infections occurred within 6 months after trial entry, most commonly respiratory tract infections (15/22, 68%). At baseline, lower absolute numbers of CD19+ cells were observed in patients with severe infections either receiving RTX or CYC/AZA at baseline, while CD5+B and CD3+T cells did not differ between groups. In Cox-regression analysis, higher baseline serum immunoglobulin M levels were associated with the risk of severe infections, whereby a higher baseline total CD19+B cell number and prophylaxis against Pneumocystis jirovecii with trimethoprim-sulfamethoxazole (TMP/SMX) with decreased risk of severe infections. Use of TMP/SMX was associated with lower risk of severe infections in both groups, receiving either RTX or CYC/AZA. CONCLUSIONS: The use of low-dose TMP/SMX is associated with reduced risk of severe infections in patients with AAV treated with either RTX or CYC/AZA. Reduced B cell subpopulations at start of treatment might be a useful correlate of reduced immunocompetence.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Odler B, Riedl R, Gauckler P, et al. Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. 2023. PMID: 36702528. doi:10.1136/ard-2022-223401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。